Hansa Biopharma signs deal with US-based gene therapy firm
Swedish biotech firm Hansa Biopharma signs million-dollar deal with US-based gene therapy company Sarepta. The deal ensures Hansa Biopharma gets USD 10 million and milestone payments of up to USD 397.5 million.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY IDA LØJMAND
There are many reasons to smile in the Swedish biotech firm Hansa Biopharma these days.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
